Don’t let the high cost of brand bismuth-based quadruple H. pylori therapy disrupt your eradication treatment. We help eligible patients access Pylera (bismuth subcitrate potassium / metronidazole / tetracycline capsules) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
The Pylera Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Pylera (used in combination with omeprazole for treatment of H. pylori infection) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but the enrollment process involves detailed applications, gastroenterology or primary care coordination, supporting documentation, and ongoing renewal — which can be overwhelming when you are dealing with a confirmed H. pylori infection and the prospect of a complex multi-drug eradication regimen.
At AffordMyPrescriptions, our Patient Advocates handle the entire Pylera PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your prescriber for required medical documentation, follow up with the manufacturer’s program until approval, manage your refills, and handle annual re-certification — so you never face a gap in your Pylera H. pylori therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Pylera enrollment — from the initial application through ongoing refills and annual re-enrollment — so you never face a gap in your H. pylori treatment.
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens (brand) | ~$780/course | Save substantially |
| CVS Pharmacy (brand) | ~$800/course | Save substantially |
| Walmart (brand) | ~$540/course | Save substantially |
| Costco(brand) | ~$500/course | Save substantially |
Generic components separately | ~$60/course | Generic components — substantial |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Pylera — independent of dosage or retail price.
1 Medications
2 Medications
3 Medications
4+ Medications
The Pylera Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management — applications that are commonly delayed or denied when paperwork is incomplete. Our $69.95 per month covers full advocacy: applications, doctor coordination, documentation, refill management, and re-enrollment — so you focus on your health, not paperwork. Bismuth-based quadruple therapy can be assembled with generic components at much lower cost — pill burden is higher but eradication rates are comparable.
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Pylera:
No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
If denied, we explore alternative savings paths on your behalf
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Pylera assistance.
Pylera is a fixed-dose combination capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline — three components of bismuth-based quadruple therapy (the fourth component is the PPI omeprazole, prescribed separately). This regimen is particularly important in areas with high clarithromycin resistance, where it achieves better eradication rates than traditional clarithromycin-based triple therapy.
How Pylera Works:
H.pylori is a gram-negative bacterium that colonizes the gastric mucosa, causing chronic gastritis, peptic ulcers, gastric MALT lymphoma, and increased risk of gastric adenocarcinoma. Eradication regimens combine multiple antibiotics with acid suppression to overcome bacterial resistance and improve drug penetration.
Pylera combines three antibacterial mechanisms: bismuth subcitrate has direct antimicrobial activity against H. pylori, disrupts the bacterial cell wall, and forms protective complexes on ulcer surfaces; metronidazole damages bacterial DNA (effective even with clarithromycin resistance); tetracycline inhibits bacterial protein synthesis. PPI omeprazole raises gastric pH — activating antibiotics and reducing bacterial division. The four-drug approach overcomes single-antibiotic resistance and improves eradication rates.
Form and Use:
Pylera capsules. Take 3 capsules four times daily (after meals and at bedtime) for 10 days. Coadminister with omeprazole 20 mg twice daily (morning and evening). Take with food. Avoid alcohol during therapy and for 1 day after (metronidazole disulfiram-like reaction). Avoid milk, antacids, calcium, iron, and other multivalent cations within 2 hours of dose (impair tetracycline absorption). Complete full 10-day course even if symptoms improve. Confirm eradication with urea breath test or stool antigen test at least 4 weeks after completing therapy.
Generic Availability:
No generic Pylera. Component generics widely available much cheaper: generic bismuth subsalicylate (Pepto-Bismol OTC tablets) or compounded bismuth subcitrate, generic metronidazole tablets, generic tetracycline capsules, generic PPI (omeprazole, lansoprazole, esomeprazole, pantoprazole, rabeprazole). Other H. pylori regimens (10–14 days): clarithromycin-based triple (PPI + amoxicillin + clarithromycin — only when local resistance < 15%), concomitant therapy (PPI + amoxicillin + clarithromycin + metronidazole — alternative to bismuth-based quadruple), sequential therapy (5 days PPI + amoxicillin, then 5 days PPI + clarithromycin + metronidazole), levofloxacin-based salvage (PPI + amoxicillin + levofloxacin), rifabutin-based salvage therapy (Talicia — brand fixed-combination with amoxicillin and omeprazole). Vonoprazan-based regimens: Voquezna Triple Pak (vonoprazan PCAB + amoxicillin + clarithromycin) or Voquezna Dual Pak (vonoprazan + amoxicillin) — newer brand options for first-line eradication. Post-treatment testing essential (urea breath test or stool antigen at least 4 weeks after completing).
Warnings:
Black tongue and dark stools (bismuth-related — harmless and reversible), nausea, diarrhea, abdominal pain, headache, dysgeusia (metallic taste from metronidazole), dizziness, photosensitivity and skin pigmentation (tetracycline). **Contraindicated**: pregnancy and breastfeeding (tetracycline — fetal teeth and bone effects; metronidazole — caution in first trimester), children <8 years (tetracycline tooth discoloration and bone effects), severe renal impairment. Drug interactions: alcohol (metronidazole disulfiram-like reaction — flushing, nausea, vomiting), warfarin (potentiated INR), lithium (metronidazole increases lithium levels), CYP3A4 metabolism considerations, antiretrovirals containing ritonavir, methotrexate. Caution: hypersensitivity to bismuth, metronidazole, or tetracyclines; CNS disorders (metronidazole rare seizure and peripheral neuropathy with prolonged use); liver disease.
Brand Pylera $500–$800 for a 10-day course. Generic components (separate bismuth, metronidazole, tetracycline, omeprazole) assembled into bismuth-based quadruple therapy cost $40–$80 total — substantial savings, though pill burden is higher.
Pylera combines three antibiotic components into a single capsule — simpler dosing, fewer pill swallowing acts, but more expensive. Generic components used separately achieve the same regimen at much lower cost but require taking multiple pills at each dose (typically 3–4 pills four times daily). Clinical eradication rates are comparable when adherence is maintained.
Clarithromycin-based triple therapy has lost effectiveness in many areas due to rising clarithromycin resistance (rates of 15%+ in many US regions). Bismuth-based quadruple therapy (Pylera + omeprazole) achieves better eradication rates in regions with clarithromycin resistance and is recommended first-line in such areas. Increasing use of vonoprazan-based regimens may shift this approach further.
Bismuth combines with sulfur in the gut to form bismuth sulfide — harmlessly darkening stools (and sometimes tongue). The discoloration reverses after stopping therapy. Not a concern unless other signs of bleeding (true black tarry stools suggesting GI bleeding need evaluation).
No — metronidazole can cause a disulfiram-like reaction with alcohol (flushing, nausea, vomiting, headache, palpitations). Avoid alcohol during the 10-day course and for at least 24–48 hours after completing therapy.
Vonoprazan is a potassium-competitive acid blocker (PCAB) that provides more potent and rapid acid suppression than PPIs. Voquezna Triple Pak combines vonoprazan with amoxicillin and clarithromycin; Voquezna Dual Pak is vonoprazan + amoxicillin. These newer regimens may offer improved eradication rates in clarithromycin-resistant disease but are also expensive. Pylera remains effective in clarithromycin-resistant settings.Our Patient Advocates will immediately explore every alternative — including the generic combination capsule ($187–$220), purchasing the individual generic components separately ($31–$82 total), GoodRx and SingleCare discounts, insurance formulary exception requests, and alternative H. pylori treatment regimens. If we cannot secure assistance, you won’t be charged.
Confirmatory testing for eradication is recommended at least 4 weeks after completing therapy — either urea breath test or stool antigen test (both highly sensitive and specific when properly timed). PPI should be held for 1–2 weeks before testing to avoid false-negative results. Persistent infection requires salvage therapy with different antibiotics.
We help explore generic component bismuth-based quadruple therapy (substantial savings — bismuth subsalicylate OTC, generic metronidazole, generic tetracycline, generic omeprazole), clarithromycin-based triple therapy if local resistance is low, manufacturer copay programs, Talicia copay (rifabutin-based brand), Voquezna copay (vonoprazan-based brand), GoodRx and SingleCare discounts on individual components, and post-treatment confirmation testing.
H. pylori eradication therapy should not be skipped over cost — untreated infection causes chronic gastritis, ulcers, and increases gastric cancer risk. Generic component bismuth-based quadruple therapy offers substantial savings vs brand Pylera. Our Pylera advocacy team is ready to verify your eligibility, complete the manufacturer application on your behalf, and manage your prescription through approval, delivery, and renewal — for a flat $69.95 per month. If we cannot help you access Pylera through a Patient Assistance Program, you are not charged. Call (833) 556-2729 or check your eligibility online today.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.